Global Pulmonary Arterial Hypertension (PAH) Therapeutics Sales Market Report 2016

November 2016 | 111 pages | ID: GF6226430A0EN
QYResearch

Abstracts

Notes:

Sales, means the sales volume of Pulmonary Arterial Hypertension (PAH) Therapeutics

Revenue, means the sales value of Pulmonary Arterial Hypertension (PAH) Therapeutics

This report studies sales (consumption) of Pulmonary Arterial Hypertension (PAH) Therapeutics in Global market, especially in United States, China, Europe, Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering

• Actelion Pharmaceuticals Ltd. (Switzerland)
• Arena Pharmaceuticals, Inc. (US)
• Bayer HealthCare Pharmaceuticals (Germany)
• Cipla Limited (India)
• Daiichi Sankyo Co., Ltd. (Japan)
• Eli Lilly and Company (US)
• Gilead Sciences, Inc. (US)
• GlaxoSmithKline Plc (UK)
• Nippon Shinyaku Co., Ltd. (Japan)
• Pfizer, Inc. (US)
• Sanofi S.A (France)
• The Novartis Group (Switzerland)
• United Therapeutics Corp. (US)
• YM BioSciences, Inc. (Canada)

Market Segment by Regions, this report splits Global into several key Regions, with sales (consumption), revenue, market share and growth rate of Pulmonary Arterial Hypertension (PAH) Therapeutics in these regions, from 2011 to 2021 (forecast), like

• United States
• China
• Europe
• Japan

Split by product Types, with sales, revenue, price and gross margin, market share and growth rate of each type, can be divided into

• Type I
• Type II
• Type III

Split by applications, this report focuses on sales, market share and growth rate of Pulmonary Arterial Hypertension (PAH) Therapeutics in each application, can be divided into

• Application 1
• Application 2
• Application 3

Contents

Global Pulmonary Arterial Hypertension (PAH) Therapeutics Sales Market Report 2016

1 PULMONARY ARTERIAL HYPERTENSION (PAH) THERAPEUTICS OVERVIEW

1.1 Product Overview and Scope of Pulmonary Arterial Hypertension (PAH) Therapeutics
1.2 Classification of Pulmonary Arterial Hypertension (PAH) Therapeutics
  1.2.1 Type I
  1.2.2 Type II
  1.2.3 Type III
1.3 Application of Pulmonary Arterial Hypertension (PAH) Therapeutics
  1.3.1 Application
  1.3.2 Application
  1.3.3 Application
1.4 Pulmonary Arterial Hypertension (PAH) Therapeutics Market by Regions
  1.4.1 United States Status and Prospect (2011-2021)
  1.4.2 China Status and Prospect (2011-2021)
  1.4.3 Europe Status and Prospect (2011-2021)
  1.4.4 Japan Status and Prospect (2011-2021)
1.5 Global Market Size (Value and Volume) of Pulmonary Arterial Hypertension (PAH) Therapeutics (2011-2021)
  1.5.1 Global Pulmonary Arterial Hypertension (PAH) Therapeutics Sales and Growth Rate (2011-2021)
  1.5.2 Global Pulmonary Arterial Hypertension (PAH) Therapeutics Revenue and Growth Rate (2011-2021)

2 GLOBAL PULMONARY ARTERIAL HYPERTENSION (PAH) THERAPEUTICS COMPETITION BY MANUFACTURERS, TYPE AND APPLICATION

2.1 Global Pulmonary Arterial Hypertension (PAH) Therapeutics Market Competition by Manufacturers
  2.1.1 Global Pulmonary Arterial Hypertension (PAH) Therapeutics Sales and Market Share of Key Manufacturers (2011-2016)
  2.1.2 Global Pulmonary Arterial Hypertension (PAH) Therapeutics Revenue and Share by Manufacturers (2011-2016)
2.2 Global Pulmonary Arterial Hypertension (PAH) Therapeutics (Volume and Value) by Type
  2.2.1 Global Pulmonary Arterial Hypertension (PAH) Therapeutics Sales and Market Share by Type (2011-2016)
  2.2.2 Global Pulmonary Arterial Hypertension (PAH) Therapeutics Revenue and Market Share by Type (2011-2016)
2.3 Global Pulmonary Arterial Hypertension (PAH) Therapeutics (Volume and Value) by Regions
  2.3.1 Global Pulmonary Arterial Hypertension (PAH) Therapeutics Sales and Market Share by Regions (2011-2016)
  2.3.2 Global Pulmonary Arterial Hypertension (PAH) Therapeutics Revenue and Market Share by Regions (2011-2016)
2.4 Global Pulmonary Arterial Hypertension (PAH) Therapeutics (Volume) by Application

3 UNITED STATES PULMONARY ARTERIAL HYPERTENSION (PAH) THERAPEUTICS (VOLUME, VALUE AND SALES PRICE)

3.1 United States Pulmonary Arterial Hypertension (PAH) Therapeutics Sales and Value (2011-2016)
  3.1.1 United States Pulmonary Arterial Hypertension (PAH) Therapeutics Sales and Growth Rate (2011-2016)
  3.1.2 United States Pulmonary Arterial Hypertension (PAH) Therapeutics Revenue and Growth Rate (2011-2016)
  3.1.3 United States Pulmonary Arterial Hypertension (PAH) Therapeutics Sales Price Trend (2011-2016)
3.2 United States Pulmonary Arterial Hypertension (PAH) Therapeutics Sales and Market Share by Manufacturers
3.3 United States Pulmonary Arterial Hypertension (PAH) Therapeutics Sales and Market Share by Type
3.4 United States Pulmonary Arterial Hypertension (PAH) Therapeutics Sales and Market Share by Application

4 CHINA PULMONARY ARTERIAL HYPERTENSION (PAH) THERAPEUTICS (VOLUME, VALUE AND SALES PRICE)

4.1 China Pulmonary Arterial Hypertension (PAH) Therapeutics Sales and Value (2011-2016)
  4.1.1 China Pulmonary Arterial Hypertension (PAH) Therapeutics Sales and Growth Rate (2011-2016)
  4.1.2 China Pulmonary Arterial Hypertension (PAH) Therapeutics Revenue and Growth Rate (2011-2016)
  4.1.3 China Pulmonary Arterial Hypertension (PAH) Therapeutics Sales Price Trend (2011-2016)
4.2 China Pulmonary Arterial Hypertension (PAH) Therapeutics Sales and Market Share by Manufacturers
4.3 China Pulmonary Arterial Hypertension (PAH) Therapeutics Sales and Market Share by Type
4.4 China Pulmonary Arterial Hypertension (PAH) Therapeutics Sales and Market Share by Application

5 EUROPE PULMONARY ARTERIAL HYPERTENSION (PAH) THERAPEUTICS (VOLUME, VALUE AND SALES PRICE)

5.1 Europe Pulmonary Arterial Hypertension (PAH) Therapeutics Sales and Value (2011-2016)
  5.1.1 Europe Pulmonary Arterial Hypertension (PAH) Therapeutics Sales and Growth Rate (2011-2016)
  5.1.2 Europe Pulmonary Arterial Hypertension (PAH) Therapeutics Revenue and Growth Rate (2011-2016)
  5.1.3 Europe Pulmonary Arterial Hypertension (PAH) Therapeutics Sales Price Trend (2011-2016)
5.2 Europe Pulmonary Arterial Hypertension (PAH) Therapeutics Sales and Market Share by Manufacturers
5.3 Europe Pulmonary Arterial Hypertension (PAH) Therapeutics Sales and Market Share by Type
5.4 Europe Pulmonary Arterial Hypertension (PAH) Therapeutics Sales and Market Share by Application

6 JAPAN PULMONARY ARTERIAL HYPERTENSION (PAH) THERAPEUTICS (VOLUME, VALUE AND SALES PRICE)

6.1 Japan Pulmonary Arterial Hypertension (PAH) Therapeutics Sales and Value (2011-2016)
  6.1.1 Japan Pulmonary Arterial Hypertension (PAH) Therapeutics Sales and Growth Rate (2011-2016)
  6.1.2 Japan Pulmonary Arterial Hypertension (PAH) Therapeutics Revenue and Growth Rate (2011-2016)
  6.1.3 Japan Pulmonary Arterial Hypertension (PAH) Therapeutics Sales Price Trend (2011-2016)
6.2 Japan Pulmonary Arterial Hypertension (PAH) Therapeutics Sales and Market Share by Manufacturers
6.3 Japan Pulmonary Arterial Hypertension (PAH) Therapeutics Sales and Market Share by Type
6.4 Japan Pulmonary Arterial Hypertension (PAH) Therapeutics Sales and Market Share by Application

7 GLOBAL PULMONARY ARTERIAL HYPERTENSION (PAH) THERAPEUTICS MANUFACTURERS ANALYSIS

7.1 Actelion Pharmaceuticals Ltd. (Switzerland)
  7.1.1 Company Basic Information, Manufacturing Base and Competitors
  7.1.2 Pulmonary Arterial Hypertension (PAH) Therapeutics Product Type, Application and Specification
    7.1.2.1 Type I
    7.1.2.2 Type II
  7.1.3 Actelion Pharmaceuticals Ltd. (Switzerland) Pulmonary Arterial Hypertension (PAH) Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)
  7.1.4 Main Business/Business Overview
7.2 Arena Pharmaceuticals, Inc. (US)
  7.2.1 Company Basic Information, Manufacturing Base and Competitors
  7.2.2 111 Product Type, Application and Specification
    7.2.2.1 Type I
    7.2.2.2 Type II
  7.2.3 Arena Pharmaceuticals, Inc. (US) Pulmonary Arterial Hypertension (PAH) Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)
  7.2.4 Main Business/Business Overview
7.3 Bayer HealthCare Pharmaceuticals (Germany)
  7.3.1 Company Basic Information, Manufacturing Base and Competitors
  7.3.2 131 Product Type, Application and Specification
    7.3.2.1 Type I
    7.3.2.2 Type II
  7.3.3 Bayer HealthCare Pharmaceuticals (Germany) Pulmonary Arterial Hypertension (PAH) Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)
  7.3.4 Main Business/Business Overview
7.4 Cipla Limited (India)
  7.4.1 Company Basic Information, Manufacturing Base and Competitors
  7.4.2 Nov Product Type, Application and Specification
    7.4.2.1 Type I
    7.4.2.2 Type II
  7.4.3 Cipla Limited (India) Pulmonary Arterial Hypertension (PAH) Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)
  7.4.4 Main Business/Business Overview
7.5 Daiichi Sankyo Co., Ltd. (Japan)
  7.5.1 Company Basic Information, Manufacturing Base and Competitors
  7.5.2 Product Type, Application and Specification
    7.5.2.1 Type I
    7.5.2.2 Type II
  7.5.3 Daiichi Sankyo Co., Ltd. (Japan) Pulmonary Arterial Hypertension (PAH) Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)
  7.5.4 Main Business/Business Overview
7.6 Eli Lilly and Company (US)
  7.6.1 Company Basic Information, Manufacturing Base and Competitors
  7.6.2 Million USD Product Type, Application and Specification
    7.6.2.1 Type I
    7.6.2.2 Type II
  7.6.3 Eli Lilly and Company (US) Pulmonary Arterial Hypertension (PAH) Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)
  7.6.4 Main Business/Business Overview
7.7 Gilead Sciences, Inc. (US)
  7.7.1 Company Basic Information, Manufacturing Base and Competitors
  7.7.2 Pharma & Healthcare Product Type, Application and Specification
    7.7.2.1 Type I
    7.7.2.2 Type II
  7.7.3 Gilead Sciences, Inc. (US) Pulmonary Arterial Hypertension (PAH) Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)
  7.7.4 Main Business/Business Overview
7.8 GlaxoSmithKline Plc (UK)
  7.8.1 Company Basic Information, Manufacturing Base and Competitors
  7.8.2 Product Type, Application and Specification
    7.8.2.1 Type I
    7.8.2.2 Type II
  7.8.3 GlaxoSmithKline Plc (UK) Pulmonary Arterial Hypertension (PAH) Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)
  7.8.4 Main Business/Business Overview
7.9 Nippon Shinyaku Co., Ltd. (Japan)
  7.9.1 Company Basic Information, Manufacturing Base and Competitors
  7.9.2 Product Type, Application and Specification
    7.9.2.1 Type I
    7.9.2.2 Type II
  7.9.3 Nippon Shinyaku Co., Ltd. (Japan) Pulmonary Arterial Hypertension (PAH) Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)
  7.9.4 Main Business/Business Overview
7.10 Pfizer, Inc. (US)
  7.10.1 Company Basic Information, Manufacturing Base and Competitors
  7.10.2 Product Type, Application and Specification
    7.10.2.1 Type I
    7.10.2.2 Type II
  7.10.3 Pfizer, Inc. (US) Pulmonary Arterial Hypertension (PAH) Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)
  7.10.4 Main Business/Business Overview
7.11 Sanofi S.A (France)
7.12 The Novartis Group (Switzerland)
7.13 United Therapeutics Corp. (US)
7.14 YM BioSciences, Inc. (Canada)

8 PULMONARY ARTERIAL HYPERTENSION (PAH) THERAPEUTICS MAUFACTURING COST ANALYSIS

8.1 Pulmonary Arterial Hypertension (PAH) Therapeutics Key Raw Materials Analysis
  8.1.1 Key Raw Materials
  8.1.2 Price Trend of Key Raw Materials
  8.1.3 Key Suppliers of Raw Materials
  8.1.4 Market Concentration Rate of Raw Materials
8.2 Proportion of Manufacturing Cost Structure
  8.2.1 Raw Materials
  8.2.2 Labor Cost
  8.2.3 Manufacturing Process Analysis of Pulmonary Arterial Hypertension (PAH) Therapeutics

9 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

9.1 Pulmonary Arterial Hypertension (PAH) Therapeutics Industrial Chain Analysis
9.2 Upstream Raw Materials Sourcing
9.3 Raw Materials Sources of Pulmonary Arterial Hypertension (PAH) Therapeutics Major Manufacturers in 2015
9.4 Downstream Buyers

10 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

10.1 Marketing Channel
  10.1.1 Direct Marketing
  10.1.2 Indirect Marketing
  10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
  10.2.1 Pricing Strategy
  10.2.2 Brand Strategy
  10.2.3 Target Client
10.3 Distributors/Traders List

11 MARKET EFFECT FACTORS ANALYSIS

11.1 Technology Progress/Risk
  11.1.1 Substitutes Threat
  11.1.2 Technology Progress in Related Industry
11.2 Consumer Needs/Customer Preference Change
11.3 Economic/Political Environmental Change

12 GLOBAL PULMONARY ARTERIAL HYPERTENSION (PAH) THERAPEUTICS MARKET FORECAST (2016-2021)

12.1 Global Pulmonary Arterial Hypertension (PAH) Therapeutics Sales, Revenue Forecast (2016-2021)
12.2 Global Pulmonary Arterial Hypertension (PAH) Therapeutics Sales Forecast by Regions (2016-2021)
12.3 Global Pulmonary Arterial Hypertension (PAH) Therapeutics Sales Forecast by Type (2016-2021)
12.4 Global Pulmonary Arterial Hypertension (PAH) Therapeutics Sales Forecast by Application (2016-2021)

13 APPENDIX

Author List
Disclosure Section
Research Methodology
Data Source
China Disclaimer

List Of Tables

LIST OF TABLES AND FIGURES

Figure Picture of Pulmonary Arterial Hypertension (PAH) Therapeutics
Table Classification of Pulmonary Arterial Hypertension (PAH) Therapeutics
Figure Global Sales Market Share of Pulmonary Arterial Hypertension (PAH) Therapeutics by Type in 2015
Figure Type I Picture
Figure Type II Picture
Table Applications of Pulmonary Arterial Hypertension (PAH) Therapeutics
Figure Global Sales Market Share of Pulmonary Arterial Hypertension (PAH) Therapeutics by Application in 2015
Figure Application 1 Examples
Figure Application 2 Examples
Figure United States Pulmonary Arterial Hypertension (PAH) Therapeutics Revenue and Growth Rate (2011-2021)
Figure China Pulmonary Arterial Hypertension (PAH) Therapeutics Revenue and Growth Rate (2011-2021)
Figure Europe Pulmonary Arterial Hypertension (PAH) Therapeutics Revenue and Growth Rate (2011-2021)
Figure Japan Pulmonary Arterial Hypertension (PAH) Therapeutics Revenue and Growth Rate (2011-2021)
Figure Global Pulmonary Arterial Hypertension (PAH) Therapeutics Sales and Growth Rate (2011-2021)
Figure Global Pulmonary Arterial Hypertension (PAH) Therapeutics Revenue and Growth Rate (2011-2021)
Table Global Pulmonary Arterial Hypertension (PAH) Therapeutics Sales of Key Manufacturers (2011-2016)
Table Global Pulmonary Arterial Hypertension (PAH) Therapeutics Sales Share by Manufacturers (2011-2016)
Figure 2015 Pulmonary Arterial Hypertension (PAH) Therapeutics Sales Share by Manufacturers
Figure 2016 Pulmonary Arterial Hypertension (PAH) Therapeutics Sales Share by Manufacturers
Table Global Pulmonary Arterial Hypertension (PAH) Therapeutics Revenue by Manufacturers (2011-2016)
Table Global Pulmonary Arterial Hypertension (PAH) Therapeutics Revenue Share by Manufacturers (2011-2016)
Table 2015 Global Pulmonary Arterial Hypertension (PAH) Therapeutics Revenue Share by Manufacturers
Table 2016 Global Pulmonary Arterial Hypertension (PAH) Therapeutics Revenue Share by Manufacturers
Table Global Pulmonary Arterial Hypertension (PAH) Therapeutics Sales and Market Share by Type (2011-2016)
Table Global Pulmonary Arterial Hypertension (PAH) Therapeutics Sales Share by Type (2011-2016)
Figure Sales Market Share of Pulmonary Arterial Hypertension (PAH) Therapeutics by Type (2011-2016)
Figure Global Pulmonary Arterial Hypertension (PAH) Therapeutics Sales Growth Rate by Type (2011-2016)
Table Global Pulmonary Arterial Hypertension (PAH) Therapeutics Revenue and Market Share by Type (2011-2016)
Table Global Pulmonary Arterial Hypertension (PAH) Therapeutics Revenue Share by Type (2011-2016)
Figure Revenue Market Share of Pulmonary Arterial Hypertension (PAH) Therapeutics by Type (2011-2016)
Figure Global Pulmonary Arterial Hypertension (PAH) Therapeutics Revenue Growth Rate by Type (2011-2016)
Table Global Pulmonary Arterial Hypertension (PAH) Therapeutics Sales and Market Share by Regions (2011-2016)
Table Global Pulmonary Arterial Hypertension (PAH) Therapeutics Sales Share by Regions (2011-2016)
Figure Sales Market Share of Pulmonary Arterial Hypertension (PAH) Therapeutics by Regions (2011-2016)
Figure Global Pulmonary Arterial Hypertension (PAH) Therapeutics Sales Growth Rate by Regions (2011-2016)
Table Global Pulmonary Arterial Hypertension (PAH) Therapeutics Revenue and Market Share by Regions (2011-2016)
Table Global Pulmonary Arterial Hypertension (PAH) Therapeutics Revenue Share by Regions (2011-2016)
Figure Revenue Market Share of Pulmonary Arterial Hypertension (PAH) Therapeutics by Regions (2011-2016)
Figure Global Pulmonary Arterial Hypertension (PAH) Therapeutics Revenue Growth Rate by Regions (2011-2016)
Table Global Pulmonary Arterial Hypertension (PAH) Therapeutics Sales and Market Share by Application (2011-2016)
Table Global Pulmonary Arterial Hypertension (PAH) Therapeutics Sales Share by Application (2011-2016)
Figure Sales Market Share of Pulmonary Arterial Hypertension (PAH) Therapeutics by Application (2011-2016)
Figure Global Pulmonary Arterial Hypertension (PAH) Therapeutics Sales Growth Rate by Application (2011-2016)
Figure United States Pulmonary Arterial Hypertension (PAH) Therapeutics Sales and Growth Rate (2011-2016)
Figure United States Pulmonary Arterial Hypertension (PAH) Therapeutics Revenue and Growth Rate (2011-2016)
Figure United States Pulmonary Arterial Hypertension (PAH) Therapeutics Sales Price Trend (2011-2016)
Table United States Pulmonary Arterial Hypertension (PAH) Therapeutics Sales by Manufacturers (2011-2016)
Table United States Pulmonary Arterial Hypertension (PAH) Therapeutics Market Share by Manufacturers (2011-2016)
Table United States Pulmonary Arterial Hypertension (PAH) Therapeutics Sales by Type (2011-2016)
Table United States Pulmonary Arterial Hypertension (PAH) Therapeutics Market Share by Type (2011-2016)
Table United States Pulmonary Arterial Hypertension (PAH) Therapeutics Sales by Application (2011-2016)
Table United States Pulmonary Arterial Hypertension (PAH) Therapeutics Market Share by Application (2011-2016)
Figure China Pulmonary Arterial Hypertension (PAH) Therapeutics Sales and Growth Rate (2011-2016)
Figure China Pulmonary Arterial Hypertension (PAH) Therapeutics Revenue and Growth Rate (2011-2016)
Figure China Pulmonary Arterial Hypertension (PAH) Therapeutics Sales Price Trend (2011-2016)
Table China Pulmonary Arterial Hypertension (PAH) Therapeutics Sales by Manufacturers (2011-2016)
Table China Pulmonary Arterial Hypertension (PAH) Therapeutics Market Share by Manufacturers (2011-2016)
Table China Pulmonary Arterial Hypertension (PAH) Therapeutics Sales by Type (2011-2016)
Table China Pulmonary Arterial Hypertension (PAH) Therapeutics Market Share by Type (2011-2016)
Table China Pulmonary Arterial Hypertension (PAH) Therapeutics Sales by Application (2011-2016)
Table China Pulmonary Arterial Hypertension (PAH) Therapeutics Market Share by Application (2011-2016)
Figure Europe Pulmonary Arterial Hypertension (PAH) Therapeutics Sales and Growth Rate (2011-2016)
Figure Europe Pulmonary Arterial Hypertension (PAH) Therapeutics Revenue and Growth Rate (2011-2016)
Figure Europe Pulmonary Arterial Hypertension (PAH) Therapeutics Sales Price Trend (2011-2016)
Table Europe Pulmonary Arterial Hypertension (PAH) Therapeutics Sales by Manufacturers (2011-2016)
Table Europe Pulmonary Arterial Hypertension (PAH) Therapeutics Market Share by Manufacturers (2011-2016)
Table Europe Pulmonary Arterial Hypertension (PAH) Therapeutics Sales by Type (2011-2016)
Table Europe Pulmonary Arterial Hypertension (PAH) Therapeutics Market Share by Type (2011-2016)
Table Europe Pulmonary Arterial Hypertension (PAH) Therapeutics Sales by Application (2011-2016)
Table Europe Pulmonary Arterial Hypertension (PAH) Therapeutics Market Share by Application (2011-2016)
Figure Japan Pulmonary Arterial Hypertension (PAH) Therapeutics Sales and Growth Rate (2011-2016)
Figure Japan Pulmonary Arterial Hypertension (PAH) Therapeutics Revenue and Growth Rate (2011-2016)
Figure Japan Pulmonary Arterial Hypertension (PAH) Therapeutics Sales Price Trend (2011-2016)
Table Japan Pulmonary Arterial Hypertension (PAH) Therapeutics Sales by Manufacturers (2011-2016)
Table Japan Pulmonary Arterial Hypertension (PAH) Therapeutics Market Share by Manufacturers (2011-2016)
Table Japan Pulmonary Arterial Hypertension (PAH) Therapeutics Sales by Type (2011-2016)
Table Japan Pulmonary Arterial Hypertension (PAH) Therapeutics Market Share by Type (2011-2016)
Table Japan Pulmonary Arterial Hypertension (PAH) Therapeutics Sales by Application (2011-2016)
Table Japan Pulmonary Arterial Hypertension (PAH) Therapeutics Market Share by Application (2011-2016)
Table Actelion Pharmaceuticals Ltd. (Switzerland) Basic Information List
Table Actelion Pharmaceuticals Ltd. (Switzerland) Pulmonary Arterial Hypertension (PAH) Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)
Figure Actelion Pharmaceuticals Ltd. (Switzerland) Pulmonary Arterial Hypertension (PAH) Therapeutics Global Market Share (2011-2016)
Table Arena Pharmaceuticals, Inc. (US) Basic Information List
Table Arena Pharmaceuticals, Inc. (US) Pulmonary Arterial Hypertension (PAH) Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)
Figure Arena Pharmaceuticals, Inc. (US) Pulmonary Arterial Hypertension (PAH) Therapeutics Global Market Share (2011-2016)
Table Bayer HealthCare Pharmaceuticals (Germany) Basic Information List
Table Bayer HealthCare Pharmaceuticals (Germany) Pulmonary Arterial Hypertension (PAH) Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)
Figure Bayer HealthCare Pharmaceuticals (Germany) Pulmonary Arterial Hypertension (PAH) Therapeutics Global Market Share (2011-2016)
Table Cipla Limited (India) Basic Information List
Table Cipla Limited (India) Pulmonary Arterial Hypertension (PAH) Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)
Figure Cipla Limited (India) Pulmonary Arterial Hypertension (PAH) Therapeutics Global Market Share (2011-2016)
Table Daiichi Sankyo Co., Ltd. (Japan) Basic Information List
Table Daiichi Sankyo Co., Ltd. (Japan) Pulmonary Arterial Hypertension (PAH) Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)
Figure Daiichi Sankyo Co., Ltd. (Japan) Pulmonary Arterial Hypertension (PAH) Therapeutics Global Market Share (2011-2016)
Table Eli Lilly and Company (US) Basic Information List
Table Eli Lilly and Company (US) Pulmonary Arterial Hypertension (PAH) Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)
Figure Eli Lilly and Company (US) Pulmonary Arterial Hypertension (PAH) Therapeutics Global Market Share (2011-2016)
Table Gilead Sciences, Inc. (US) Basic Information List
Table Gilead Sciences, Inc. (US) Pulmonary Arterial Hypertension (PAH) Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)
Figure Gilead Sciences, Inc. (US) Pulmonary Arterial Hypertension (PAH) Therapeutics Global Market Share (2011-2016)
Table GlaxoSmithKline Plc (UK) Basic Information List
Table GlaxoSmithKline Plc (UK) Pulmonary Arterial Hypertension (PAH) Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)
Figure GlaxoSmithKline Plc (UK) Pulmonary Arterial Hypertension (PAH) Therapeutics Global Market Share (2011-2016)
Table Nippon Shinyaku Co., Ltd. (Japan) Basic Information List
Table Nippon Shinyaku Co., Ltd. (Japan) Pulmonary Arterial Hypertension (PAH) Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)
Figure Nippon Shinyaku Co., Ltd. (Japan) Pulmonary Arterial Hypertension (PAH) Therapeutics Global Market Share (2011-2016)
Table Pfizer, Inc. (US) Basic Information List
Table Pfizer, Inc. (US) Pulmonary Arterial Hypertension (PAH) Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)
Figure Pfizer, Inc. (US) Pulmonary Arterial Hypertension (PAH) Therapeutics Global Market Share (2011-2016)
Table Sanofi S.A (France) Basic Information List
Table Sanofi S.A (France) Pulmonary Arterial Hypertension (PAH) Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)
Figure Sanofi S.A (France) Pulmonary Arterial Hypertension (PAH) Therapeutics Global Market Share (2011-2016)
Table The Novartis Group (Switzerland) Basic Information List
Table The Novartis Group (Switzerland) Pulmonary Arterial Hypertension (PAH) Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)
Figure The Novartis Group (Switzerland) Pulmonary Arterial Hypertension (PAH) Therapeutics Global Market Share (2011-2016)
Table United Therapeutics Corp. (US) Basic Information List
Table United Therapeutics Corp. (US) Pulmonary Arterial Hypertension (PAH) Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)
Figure United Therapeutics Corp. (US) Pulmonary Arterial Hypertension (PAH) Therapeutics Global Market Share (2011-2016)
Table YM BioSciences, Inc. (Canada) Basic Information List
Table YM BioSciences, Inc. (Canada) Pulmonary Arterial Hypertension (PAH) Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)
Figure YM BioSciences, Inc. (Canada) Pulmonary Arterial Hypertension (PAH) Therapeutics Global Market Share (2011-2016)
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Pulmonary Arterial Hypertension (PAH) Therapeutics
Figure Manufacturing Process Analysis of Pulmonary Arterial Hypertension (PAH) Therapeutics
Figure Pulmonary Arterial Hypertension (PAH) Therapeutics Industrial Chain Analysis
Table Raw Materials Sources of Pulmonary Arterial Hypertension (PAH) Therapeutics Major Manufacturers in 2015
Table Major Buyers of Pulmonary Arterial Hypertension (PAH) Therapeutics
Table Distributors/Traders List
Figure Global Pulmonary Arterial Hypertension (PAH) Therapeutics Sales and Growth Rate Forecast (2016-2021)
Figure Global Pulmonary Arterial Hypertension (PAH) Therapeutics Revenue and Growth Rate Forecast (2016-2021)
Table Global Pulmonary Arterial Hypertension (PAH) Therapeutics Sales Forecast by Regions (2016-2021)
Table Global Pulmonary Arterial Hypertension (PAH) Therapeutics Sales Forecast by Type (2016-2021)
Table Global Pulmonary Arterial Hypertension (PAH) Therapeutics Sales Forecast by Application (2016-2021)